Cargando…
NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ(42,) in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
INTRODUCTION: Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. METHODS: Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques...
Autores principales: | Kounnas, Maria Z., Lane-Donovan, Courtney, Nowakowski, Dan W., Herz, Joachim, Comer, William T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421551/ https://www.ncbi.nlm.nih.gov/pubmed/28497107 http://dx.doi.org/10.1016/j.trci.2016.09.003 |
Ejemplares similares
-
NGP 555, a γ-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses
por: Kounnas, Maria Z., et al.
Publicado: (2019) -
Timer 555 /
por: Chapol Chipol, Carlos
Publicado: (2002) -
The decline of domiciliary dentistry
por: Emanuel, Robert, et al.
Publicado: (2021) -
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
por: Kirsebom, Bjørn-Eivind, et al.
Publicado: (2018) -
Adolescents' Lived Experiences While Hospitalized After Surgery for Ulcerative Colitis
por: Olsen, Ida Østrup, et al.
Publicado: (2016)